Clinical performance and acceptability of self-collected vaginal and urine samples compared with clinician-taken cervical samples for HPV testing among women referred for colposcopy. A cross-sectional study ============================================================================================================================================================================================================== * Dorthe Ørnskov * Kirsten Jochumsen * Pernille Husted Steiner * Ivan Moulun Grunnet * Annemette Wildfang Lykkebo * Marianne Waldstrøm ## Abstract **Objectives** To increase effectiveness of the cervical cancer screening program, self-sampling can be an option. Both self-collected vaginal samples (SCV) and urine samples may be useful alternatives to clinician-taken cervical samples (CS). **Design** Cross-sectional study. **Setting** Colposcopy clinic. **Participants** Women (n=305) referred to colposcopy after abnormal cervical screening result or conditions like postcoital bleeding. **Intervention** All women self-collected a urine and a vaginal sample prior to colposcopy, where a CS and biopsies were taken. All samples were tested for high-risk human papillomavirus (HPV) using the Cobas HPV assay. The gold standard was histology diagnoses (CIN2+/CIN3+) from biopsies obtained at the same examination. **Primary outcome** Absolute and relative sensitivity and specificity of HPV testing on SCV and urine to detect CIN2+/CIN3+ compared with the CS. **Secondary outcome** The acceptability by women of self-sampling. **Results** Both the vaginal and urine sample were comparable to the CS in identifying severe intraepithelial neoplasia (CIN2+/CIN3+). Absolute sensitivity ranged from 93% for urine samples to 96% for SCV for detecting CIN2+, which is comparable to the sensitivity of CS (overlapping 95% CI). The relative sensitivity for detecting CIN2+ was 1.00 (95% CI 0.96 to 1.04) for SCV and 0.96 (95% CI 0.91 to 1.03) for urine samples. At CIN3+, the relative sensitivity was 1.00 (95% CI 0.96 to 1.08) and 0.97 (95% CI 0.89 to 1.07) for SCV and urine samples, respectively. There were no statistical differences between the self-collected samples and the CS (McNemar’s test >0.05). The relative specificity was also similar (1.03 (95% CI 0.95 to 1.12) for SCV and 0.98 (95% CI 0.89 to 1.09) for urine samples) (McNemar’s test >0.05). The acceptability of self-sampling was evaluated by questionnaire. The women found the instructions on sample collection easy to understand and were positive about self-sampling with a preference for the urine sample. **Conclusion** Self-sampling by SCV and urine is a clinically safe alternative to CS with a high degree of acceptability. * pathology * molecular diagnostics * gynaecological oncology * public health ### Strengths and limitation of this study * All samples were collected at the same visit, including the biopsies. * Only women with all samples available for human papillomavirus (HPV) testing and biopsies were included in the study. * The HPV status was unknown to the pathologist on diagnoses. * The women’s preference towards self-sampling was examined. * The study was performed in colposcopy clinics enrolling primarily women referred with abnormal screening results and not in a screening population. ## Introduction Denmark has a tradition of >50 years for screening for cervical cancer, which has effectively decreased the incidence and mortality of the disease.1 2 However, the incidence of cervical cancer is still relatively high compared with other high-income countries.2 3 One major issue is that only 73% of the eligible women attend the screening programme, and half of the cervical cancers are diagnosed among non-attendees.4 5 Some of the barriers against attending the screening programme have been reported to be discomfort during the gynaecological examination, embarrassment, forgetting to make an appointment, fear of pain, fear of cancer, feeling healthy and not being in risk of developing cervical cancer.6–8 Some of these barriers may be reduced by offering the possibility of self-sampling.9–13 Accordingly, several studies have investigated the clinical performance of self-collected vaginal samples (SCV) compared with clinician-taken cervical samples (CS) in order to detect cervical cancer or precancer. A meta-analysis, including 36 studies, concluded that the sensitivity and specificity of an SCV were non-inferior to that of a clinician-taken CS when a clinically validated PCR-based human papillomavirus (HPV) DNA assay was used. However, it is still recommended to do feasibility studies assessing clinical accuracy, population compliance, logistics and for evaluation of costs before more widespread implementation.14 15 An alternative specimen to a vaginal sample is urine. Urine is desirable as sample material as the collection is non-invasive, and the procedure is well accepted by women.16–18 However, conflicting data have been published on the sensitivity of urine samples. Some papers have shown that urine has a lower clinical sensitivity compared with SCV and clinician-obtained samples,19 20 which may be caused by a lower viral load in the urine sample.21 In contrast, other studies have shown high concordance between urine samples and clinician-taken vaginal samples.22 23 These differences may be explained by variations in collection and processing procedures for urine samples. It has also been discussed whether first-void, mid-stream or morning urine is better for detection of HPV, but no clear conclusion can be made.17 23–26 Preservation, storage and processing methods for urine samples have been studied, and data have indicated that it was favourable to use preservation of fresh urine samples to avoid degradation of HPV DNA and to prevent inhibition of the subsequent HPV detection.27 28 Overall, there is still a need for further studies to uncover urine as test material. In Denmark, SCV for cervical cancer screening have routinely been offered to non-attendees in one out of five regions since 2018.29 A study carried out in the Central Denmark Region has shown promising results in increasing participation by employing a mailing strategy, where a test kit was send directly to the woman, as an alternative to a standard second reminder to attend screening.30 This is in line with the data from a meta-analysis, where efficiency to reach underscreened women was higher when offering self-sampling compared with receiving a reminder.31 A nationwide offer to non-attendees on self-sampling for cervical cancer screening is currently being planned by the Danish National Steering Committee for cervical cancer screening for expected implementation in 2021. However, before implementing self-sampling as a part of the Danish screening programme, it is very important to evaluate the performance of a given self-sampling set-up, that is, the combination of specific HPV assay, sampling device and material.1 14 Accordingly, the aim of the present study was to examine the clinical performance of urine samples, SCV and clinician-taken CS to detect severe intraepithelial lesions (CIN2+/CIN3+). All materials were analysed by HPV testing and the study was carried out in a Danish colposcopy setting. We also investigated the women’s preference towards self-collected vaginal and urine samples using a questionnaire. ## Materials and methods ### Study design Women referred for colposcopy at the gynaecological departments at Lillebaelt Hospital (Kolding) and Odense University Hospital (Odense and Svendborg Hospitals) in Denmark were offered to participate in this study. The women were referred either because of an abnormal screening sample or because of symptoms like postcoital bleeding. Before arriving at the hospital, all women received written information about the study. At the hospital, after filling out the informed consent, an Evalyn Brush (Rovers Medical Devices, Oss, the Netherlands) for the CS collection and a 50 mL conical tube for the urine sample were handed out together with written instructions on how to collect the two samples. The participants were also asked to fill out a short questionnaire about self-sampling. The women collected the samples in privacy before the scheduled examination. During the colposcopy, the gynaecologist routinely collected a CS in ThinPrep Media (Hologic, Marlborough, Massachusetts, USA) and cervical biopsies, when clinically relevant. In this present study, only women with cervical biopsies were included. ### Patient and public involvement There were no patient involved in the design or outcome measures of the study. But all participants were given the opportunity to see the final results at the end of the study. ### Study population A total of 359 women were enrolled over a period of 20 months from December 2016 to August 2018. Eleven women were subsequently excluded due to missing informed consent formulas and two due to missing questionnaire. As outlined in the Consolidated Standards of Reporting Trials flow diagram in figure 1, we did not receive all four sample specimens from all women (urine sample, SCV, CS and biopsies). In addition, three samples were found to be inadequate for cytology examination during testing in the laboratory; one sample had an invalid HPV test result and three samples were lost in the laboratory. Consequently, the results in this study are based on 305 women with all four sample specimens and valid test results (figure 1). The median age of the 305 women was 34 years ranging from 17 to 85 years. ![Figure 1](http://bmjopen.bmj.com/http://bmjopenuat.stage.highwire.org/content/bmjopen/11/3/e041512/F1.medium.gif) [Figure 1](http://bmjopen.bmj.com/content/11/3/e041512/F1) Figure 1 Consolidated Standards of Reporting Trials flow diagram. HPV, human papillomavirus. ### Sampling procedures The first sample collected by the woman was the urine sample. Earlier studies have discussed the need for processing of urine to improve sensitivity of HPV testing,17 27 32 and therefore a small pilot study was conducted evaluating the impact of temperature, centrifugation, collection time (first void or full-voided) and preservation (data not shown). Consequently, the following instruction for urine sampling and handling was prepared: a minimum of 8 mL full-voided urine was poured into a 50 mL tube containing 8 mL EDTA (0.5 M, pH 8). Within 5 days, the urine sample was shipped to the laboratory. The sample was centrifuged for 10 min at 1500 rpm, and the pellet was re-suspended in 2 mL PreservCyt solution (Hologic). The sample was then stored at room temperature until HPV testing. The second sample to be collected by the woman was the vaginal sample using the Evalyn Brush. At the Pathology Department, the material on the Evalyn Brush was suspended in a ThinPrep vail (Hologic), and then stored at room temperature until HPV testing. Afterwards, the questionnaire on the use of self-sampling was filled out. ### Sample processing At the Pathology Department at Lillebaelt Hospital, Vejle both the HPV test and cytology was performed. The cervical biopsies were examined at the Pathology Department at either Odense University Hospital or Lillebaelt Hospital. The CS were analysed routinely by cytology before HPV testing was performed on the residual material. The cytology slides were processed on the ThinPrep5000 Autoloader Instrument, Hologic according to the manufacturer’s instructions and stained with ThinPrep Stain. The slides were scanned by the Thin Prep Imaging System with selection of 22 fields of view, which were reviewed by a cytotechnologist in a review scope. Specimens were examined for adequacy and abnormal cells, and the threshold for an abnormal/positive sample was set as atypical squamous cells of unknown significance or more (ASCUS+). If abnormal cells were detected, a pathologist made the final diagnosis. All cytology was classified using the Bethesda Nomenclature.33 34 The histology was evaluated as part of the routine and reported using the CIN (cervical intraepithelial neoplasia) classification. The cytology and histology results were subsequently extracted from ‘Patobank’, a nationwide pathology register containing all cytological and histological diagnoses in Denmark. The histology result was used as the gold standard for evaluation of the ability of the different samples to detect severe lesions on the cervix (CIN2+/CIN3+). ### Detection of high-risk HPV DNA Detection of high-risk HPV was performed using the Cobas HPV assay automated on the Cobas 4800 instrument (Roche, Heidelberg, Germany). The Cobas system integrates sample preparation (including DNA extraction and set-up of PCR) and real-time PCR for detection of 12 HR-HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) as a pooled result, whereas HPV16 and HPV18 are reported individually. Β-globin is used as internal control to access sample adequacy and possible inhibition of the real-time PCR. ### Statistical analysis The performance of the self-collected samples were evaluated by calculating the absolute and relative sensitivity and specificity including the 95% CI. For assessing the significance of the relative sensitivity and specificity, McNemar’s test was used with a significance threshold of 0.05. Concordance between the three samples (CS, SCV and urine) was calculated using Cohen’s kappa statistics. The percentage of HPV-positive samples in the CS (control) group was estimated to be 80%, whereas the percentage of positive results in the test groups (Evalyn Brush and urine sample) was expected to be lower. With a power of 80% (significance level of 0.05) and the ability to show a difference in HPV-positive samples of 10% between control and test group, a minimum of 300 women were to be enrolled in the study. ## Results ### Detection of high-risk HPV In table 1, the HPV test results from the SCV, the urine samples and the CS are presented together with the cytology results according to the histological diagnosis made based on the concurrent biopsies. View this table: [Table 1](http://bmjopen.bmj.com/content/11/3/e041512/T1) Table 1 HPV tests and cytology results in relation to the histological results in the different sample specimens The overall HPV positivity rate was similar for SCV, the urine samples and CS, showing positive percentages of 65.6%, 63.0% and 64.3%, respectively. One squamous cell carcinoma and two adenocarcinoma in situ were detected and the corresponding SCV, urine and CS were all positive for high-risk HPV. Thirty-six samples were diagnosed as CIN3 and 35 (97%) of these samples were HPV positive in the SCV and CS, while in urine 34 (94%) samples were HPV positive. For CIN2 at total of 30 cases were detected and 28 (93%) of the SCV and CS were HPV positive, whereas the HPV positivity was marginally lower (27 HPV-positive samples) in the urine samples. The vast majority of the samples detected with CIN1 was HPV positive, but variation was seen between the three specimens; the highest HPV positivity rate was found in the CS (98%), followed by the SCV (93%). In the urine samples, the positivity rate was only 84%. Women with normal histology results presented a HPV positivity rate quite similar in all three sample specimens (48% for SCV, 47% for urine samples and 45% for the CS). Looking at the cytology results, ASCUS or more was detected in 40% of the 305 samples. This is significantly lower (p<0.0001) than the HPV positivity rates detected for CIN2 or more for the SCV, urine and CS, where 66%, 63% and 64% were HPV positive, respectively. The woman diagnosed with carcinoma had an abnormal cytology result. ### Detection of CIN2+/CIN3+ In table 2A, the absolute sensitivity and specificity are shown. For detecting CIN2+, 66 of the SCV and CS samples were true positive while 3 samples were false negative, whereas for urine 64 samples were true positive and 5 samples were false negative. For detecting CIN3+, 38 SCV and CS were true positives and 1 false negative, whereas for urine 37 samples were true positives and 2 false negative. No differences in sensitivity were observed between the three sample specimens indicated by the overlapping CIs. Our results showed that both self-collected sample specimens were non-inferior compared with the clinician-taken CS in identifying CIN2+ and CIN3+. View this table: [Table 2A](http://bmjopen.bmj.com/content/11/3/e041512/T2) Table 2A Absolute sensitivity and specificity for detecting CIN2+ and CIN3+ for the different samples View this table: [Table 2B](http://bmjopen.bmj.com/content/11/3/e041512/T3) Table 2B Relative sensitivity and specificity for the self-collected sample versus the clinician-taken cervical sample For cytology, the sensitivity for identifying CIN2+ and CIN3+ was markedly lower than that of HPV testing for all three types of samples. For CIN2+, 59 samples had ASCUS or more, while 10 were false negative. For CIN3+, 35 samples were ASCUS+ and 4 were false negative. However, the specificity of cytology was significantly better for detection of both CIN2+ and CIN3+ compared with the HPV-tested specimens. The relative sensitivity and specificity for SCV and urine samples compared with the CS are shown in table 2B. For CIN2+ and CIN3+, the sensitivity of urine and SCV are comparable to the CS with relative specificity of 1 or very close to 1 and all with CIs overlapping 1. The p values for the McNemar’s test were all above 0.05. Likewise, no difference was seen at